Spike In Drug Recalls Expected As US FDA Resumes Inspections, Targeting COVID-19-Related Problems
Executive Summary
Attorneys and recall consultants say any firm distributing products associated with COVID-19 should expect to receive the highest level of scrutiny as the US FDA resumes inspections and uses its enforcement muscle to prohibit companies from making adulterated products, such as hand sanitizers, or making fraudulent claims.